Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
Condition: Breast Neoplasms Interventions: Drug: Denosumab 120 mg; Drug: Denosumab 60 mg Sponsors: Borstkanker Onderzoek Groep; Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials